4.7 Article

Heart disease risk factors predict erectile dysfunction 25 years later - The Rancho Bernardo Study

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 43, 期 8, 页码 1405-1411

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2003.11.041

关键词

-

资金

  1. NHLBI NIH HHS [U01-HL40154] Funding Source: Medline
  2. NIA NIH HHS [AG-07181] Funding Source: Medline
  3. NIDDK NIH HHS [DK-31801] Funding Source: Medline

向作者/读者索取更多资源

OBJECTIVES We examined whether common coronary heart disease (CHD) risk factors measured in mid-life predict erectile dysfunction (ED) 25 years later. BACKGROUND Retrospective and cross-sectional studies have suggested that ED is associated with classic CHD risk factors, but few prospective studies have studied these associations. METHODS In this prospective study of community-dwelling men age 30 to 69 years, seven classic CHD risk factors (age, smoking, hypertension, diabetes, hypercholesterolemia, hypertriglyceridemia, and obesity) were assessed from 1972 to 1974. In 1998, after an average follow-up of 25 years, surviving male participants were asked to complete the International Index of Erectile Function (IIEF-5), which allows stratification of ED into five groups. RESULTS Sixty-eight percent of the surviving men returned, and 60% completed the IIEF-5 questionnaire. Respondents had more favorable levels of all heart disease risk factors at baseline than non-respondents. At baseline, the average age of the 570 ED study participants was 46 years; at follow-up, their average age was 72 years. Mean age, body mass index, cholesterol, and triglycerides were each significantly associated with an increased risk of ED. Cigarette smoking was marginally more common in those with severe/complete ED, as compared with those without ED. Blood pressure and fasting blood glucose were not significantly associated with ED, likely due to selective mortality. CONCLUSIONS Improving CHD risk factors in mid-life may decrease the risk of ED as well as CHD. Erectile dysfunction should be included as an outcome in clinical trials of lipid-lowering agents and lifestyle modifications. (C) 2004 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据